Heartland Bank & Trust Co Acquires 4,860 Shares of Johnson & Johnson (NYSE:JNJ)

Heartland Bank & Trust Co grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 108.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,346 shares of the company's stock after purchasing an additional 4,860 shares during the quarter. Johnson & Johnson makes up about 0.8% of Heartland Bank & Trust Co's investment portfolio, making the stock its 29th largest holding. Heartland Bank & Trust Co's holdings in Johnson & Johnson were worth $1,550,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Masso Torrence Wealth Management Inc. grew its position in shares of Johnson & Johnson by 18.6% during the first quarter. Masso Torrence Wealth Management Inc. now owns 5,552 shares of the company's stock worth $921,000 after purchasing an additional 872 shares in the last quarter. Absher Wealth Management LLC boosted its stake in Johnson & Johnson by 1.2% in the 1st quarter. Absher Wealth Management LLC now owns 215,584 shares of the company's stock worth $35,752,000 after purchasing an additional 2,469 shares during the period. Inlight Wealth Management LLC purchased a new stake in Johnson & Johnson during the 1st quarter valued at approximately $121,000. Intact Investment Management Inc. raised its position in shares of Johnson & Johnson by 3.2% during the first quarter. Intact Investment Management Inc. now owns 87,289 shares of the company's stock valued at $14,476,000 after buying an additional 2,700 shares during the last quarter. Finally, Burt Wealth Advisors lifted its holdings in shares of Johnson & Johnson by 3.1% in the first quarter. Burt Wealth Advisors now owns 12,778 shares of the company's stock worth $2,119,000 after buying an additional 381 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on JNJ. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Barclays cut their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Royal Bank Of Canada restated an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Thursday, June 5th. Finally, Raymond James Financial reduced their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Trading Down 0.0%

NYSE:JNJ traded down $0.03 during midday trading on Thursday, hitting $152.25. 7,147,523 shares of the company traded hands, compared to its average volume of 8,011,647. The firm has a market capitalization of $366.33 billion, a P/E ratio of 16.94, a P/E/G ratio of 2.31 and a beta of 0.42. The firm's fifty day moving average is $153.85 and its 200-day moving average is $153.69. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a $1.30 dividend. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.42%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.